---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-224253"
form_type: "8-K"
ticker: "TNGX"
cik: "0001819133"
company_name: "Tango Therapeutics, Inc."
filed_at: "2023-08-30T23:59:59+00:00"
generated_at: "2026-06-11T02:03:33.952424+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# Tango Therapeutics director Aaron Davis resigns; John Ketchum appointed to board

## Summary
- Aaron Davis resigned from board effective Aug 28, 2023; no disagreement with management.
- John Ketchum appointed as Class III director effective Aug 29, 2023; will stand for election at 2024 annual meeting.
- Ketchum receives option for 60,000 shares at $7.19, RSU for 10,000 shares, and $40k annual retainer.
- Ketchum deemed independent under Nasdaq rules; no committee assignments yet.

## SEC filing metadata
- accession: 0001193125-23-224253
- form_type: 8-K
- ticker: TNGX
- cik: 0001819133
- company_name: Tango Therapeutics, Inc.
- filed_at: 2023-08-30T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1819133/000119312523224253/0001193125-23-224253-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1819133/000119312523224253/d532996d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-224253
- JSON: https://secwatch.observer/filing/0001193125-23-224253.json
- Plain text: https://secwatch.observer/filing/0001193125-23-224253.txt

## Key facts
- Executive change
  Aaron Davis resigned as Member of the Board of Directors, Class III director at Tango Therapeutics, Inc..
  - Action: resigned
  - Role: Member of the Board of Directors, Class III director
  source text: On August 28, 2023, Aaron Davis, a member of the Board of Directors of Tango Therapeutics, Inc. (the “Company”), serving as a Class III director, notified the Company that he is resigning from the Company’s Board of Directors (the “Board”), effective immediately.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1819133/000119312523224253/0001193125-23-224253-index.htm
- Executive change
  John Ketchum was appointed as Director (Class III) at Tango Therapeutics, Inc..
  - Action: appointed
  - Role: Director (Class III)
  source text: Effective August 29, 2023, the Board appointed John Ketchum as a director of the Company to fill the newly created vacancy on the Board resulting from Mr. Davis’s resignation.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1819133/000119312523224253/0001193125-23-224253-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.